Want to see AU:HPC full AI Analyst Report?
Top Page
Hydration Pharmaceuticals Co. Ltd.
(Sydney:HPC)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.01
▲(0.00% Upside)
Action:Reiterated
Date:08/04/26
The score is primarily weighed down by weak financial performance, driven by volatile revenue, large operating losses, and persistent negative operating/free cash flow. With no usable technical indicators, technical analysis contributes a neutral impact, while valuation is slightly negative due to a negative P/E and no dividend yield data.
Positive Factors
Low financial leverage
The reported absence of debt in 2024–2025 materially lowers interest and refinancing pressure, giving the company greater solvency resilience. Over a 2–6 month horizon this preserves optionality to raise capital or restructure without heavy fixed finance costs, aiding stability while cash burn is addressed.
Negative Factors
Persistent negative cash flow
Chronic operating cash outflows and a materially larger 2025 cash burn signal the business is not self-funding and depends on external capital. Over 2–6 months this reduces financial flexibility, increases refinancing risk, and limits the firm's ability to invest in growth or stabilize operations without dilutive or costly funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
The reported absence of debt in 2024–2025 materially lowers interest and refinancing pressure, giving the company greater solvency resilience. Over a 2–6 month horizon this preserves optionality to raise capital or restructure without heavy fixed finance costs, aiding stability while cash burn is addressed.
Read all positive factors
Hydration Pharmaceuticals Co. Ltd. (HPC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.69M
Dividend YieldN/A
Average Volume (3M)1.21M
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees3
SectorConsumer Defensive
Sector Strength42
IndustryFood Distribution
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding537,988,460
10 Day Avg. Volume3,315,133
30 Day Avg. Volume1,207,806
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.91
Price to Sales (P/S)0.51
P/FCF Ratio-0.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hydration Pharmaceuticals Co. Ltd. Business Overview & Revenue Model
Company Description
The Hydration Pharmaceuticals Company Limited, established in 2001, provides a diverse portfolio of healthy hydration remedies, offered as liquids, tablets, and powders. Operating from its headquarters in San Diego, California, the company distrib...
How the Company Makes Money
null...
Hydration Pharmaceuticals Co. Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.56M | 3.20M | 10.04M | 9.10M | 6.13M |
| Gross Profit | -27.42K | 1.62M | 5.39M | 4.70M | 2.79M |
| EBITDA | -3.26M | -3.91M | -7.46M | -10.52M | -6.08M |
| Net Income | -2.96M | 2.67M | -8.10M | -10.61M | -8.97M |
Balance Sheet | |||||
| Total Assets | 2.19M | 5.00M | 6.69M | 10.39M | 15.31M |
| Cash, Cash Equivalents and Short-Term Investments | 1.12M | 3.22M | 1.84M | 4.69M | 10.67M |
| Total Debt | 0.00 | 0.00 | 3.89M | 3.71M | 0.00 |
| Total Liabilities | 774.76K | 2.25M | 7.05M | 6.41M | 2.08M |
| Stockholders Equity | 1.42M | 2.74M | -358.25K | 3.98M | 13.23M |
Cash Flow | |||||
| Free Cash Flow | -3.78M | -3.02M | -5.73M | -9.75M | -8.08M |
| Operating Cash Flow | -3.78M | -3.02M | -5.73M | -9.75M | -8.08M |
| Investing Cash Flow | 0.00 | 9.44M | 0.00 | 0.00 | -2.15K |
| Financing Cash Flow | 833.93K | -3.63M | 2.72M | 4.08M | 17.03M |
Hydration Pharmaceuticals Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | AU$152.80M | 17.11 | 12.22% | 2.27% | 27.60% | 96.31% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | AU$81.37M | 21.43 | 8.70% | ― | 23.29% | ― | |
42 Neutral | AU$2.69M | -0.49 | -139.90% | ― | ― | ― | |
42 Neutral | AU$12.60M | -2.67 | -19.17% | ― | 44.25% | 41.58% | |
40 Underperform | AU$13.33M | -2.78 | -41.69% | ― | 53.69% | 45.24% | |
39 Underperform | AU$6.66M | -0.01 | 226.76% | ― | -32.83% | 83.37% |
* Consumer Defensive Sector Average
AU:HPC
Hydration Pharmaceuticals Co. Ltd.
0.01
0.00
0.00%
AU:AHF
Australian Dairy Nutritionals Group
0.02
-0.03
-61.90%
AU:BUB
Bubs Australia Ltd.
0.09
-0.06
-40.00%
AU:NUC
Nuchev Pty Ltd
0.09
-0.08
-46.88%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
>-0.01
-9.09%
AU:CLV
Clover Corporation Limited
0.91
0.36
66.67%
Hydration Pharmaceuticals Co. Ltd. Corporate Events
Hydralyte USA Boosts Sales and Tightens Costs Amid Strategic Review
Jul 31, 2026
Hydration Pharmaceuticals Co. Ltd., trading as Hydralyte USA, operates in the hydration solutions industry, selling electrolyte products across online and offline channels in North America. The company is focusing on cost control, margin enhanceme...
Hydration Pharmaceuticals appoints new director without equity stake
Jul 1, 2026
Hydration Pharmaceuticals Co. Ltd. has appointed Nick Katiforis as a director effective 24 June 2026, expanding its board as disclosed in an initial director’s interest notice to the ASX. The filing confirms that Katiforis currently holds no...
Hydration Pharmaceuticals Director Karafili Steps Down but Retains Significant Indirect Stake
Jul 1, 2026
Hydration Pharmaceuticals Company Limited has announced that director Adem Karafili ceased to serve as a director on 24 June 2026, formally notifying the ASX in line with listing rule requirements. The notice confirms that while Karafili holds no ...
Hydralyte USA completes major share issue and reshapes board
Jun 23, 2026
Hydration Pharmaceuticals Company Limited, known as Hydralyte USA, is a hydration solutions provider listed on the ASX that offers oral rehydration products to consumers and is positioning itself for further expansion in its market. The company co...
Hydration Pharmaceuticals Seeks ASX Quotation for 98 Million New Shares
Jun 23, 2026
The Hydration Pharmaceuticals Company Limited has applied for quotation on the ASX of 98,000,000 ordinary fully paid shares under the code HPC, with an issue date of June 23, 2026. The move formalises the listing of these securities, expanding the...
Hydration Pharmaceuticals Plans Major Share Placement on ASX
Jun 17, 2026
Hydration Pharmaceuticals has notified the ASX of a proposed equity issue comprising up to 98 million ordinary fully paid shares under a placement or similar structure. The securities are intended for quotation on the ASX from 17 June 2026, signal...
Hydration Pharmaceuticals Refocuses HydraLyte Strategy on U.S. Market
May 29, 2026
Hydration Pharmaceuticals has repositioned itself as a pure-play U.S. hydration business after selling its Canadian and rest-of-world operations in October 2024 and having previously divested its Australian business in 2014. The company now concen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.